-
公开(公告)号：EP3241549A1
公开(公告)日：2017-11-08
申请号：EP17169102.5
申请日：2017-05-02
IPC分类号： A61K9/48 , A61K9/50 , A61K31/137
CPC分类号： A61K9/1676 , A61K9/2054 , A61K9/48 , A61K9/4858 , A61K9/4891 , A61K9/5015 , A61K9/5047 , A61K9/5078 , A61K31/137
摘要： The present invention relates to a sprinkle composition of cinacalcet which provides a dissolution profile which is comparable to the currently marketed tablet dosage form.
摘要翻译： 本发明涉及西那卡塞的喷洒组合物，其提供与目前市售的片剂剂型相当的溶出曲线。
-
22.发明公开PHARMACEUTICAL GASTRO-RETENTIVE SOLID ORAL DOSAGE FORM OF NILOTINIB 审中-公开MAGENSAFTRESSTENTE PHARMAZEUCHSCHE FESTE ORALE DARREICHUNGSFORM VON NILOTINIB
公开(公告)号：EP2988729A1
公开(公告)日：2016-03-02
申请号：EP14726204.2
申请日：2014-04-25
发明人： FANDA, Anuj, Kumar , SHARMA, Ravish , VIVEK, Kumaravel , KHURANA, Lalit, Kumar , AHMAD, Shavej , SINGH, Romi, Barat , SINGLA, Ajay, Kumar
IPC分类号： A61K9/00 , A61K9/16 , A61K9/20 , A61K31/506
CPC分类号： A61K31/506 , A61K9/0004 , A61K9/0065 , A61K9/20 , A61K9/4891
摘要： The present invention relates to a pharmaceutical gastro-retentive solid oral dosage form comprising nilotinib as the active ingredient. The invention is further related to methods of preparing said dosage form.
摘要翻译： 本发明涉及包含尼罗替尼作为活性成分的药物保持性固体口服剂型。 本发明还涉及制备所述剂型的方法。
-
公开(公告)号：EP2659902A1
公开(公告)日：2013-11-06
申请号：EP13165890.8
申请日：2013-04-30
发明人： George, Alex , Kane, Prashant , Bhowmick, Subhas
CPC分类号： A61M5/31593 , A61K9/0019 , A61K9/08 , A61K38/09 , A61K47/10 , A61M5/3146 , A61M5/3155 , A61M5/3202 , A61M2005/3126
摘要： The present invention provides a sterile solution comprising leuprolide acetate in a pharmaceutically acceptable vehicle, wherein solution is present as a reservoir in a multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the said reservoir in a single daily dose and further being adapted to provide multiple portions of solution said while the reservoir remains sterile.
摘要翻译： 本发明提供了一种无菌溶液，其包含在药学上可接受的载体中的醋酸亮丙瑞林，其中溶液作为储库存在于多剂量笔式注射装置中，该装置适于以单一日剂量皮下注射所述储库的一部分，和 进一步适于在所述贮存器保持无菌状态时提供所述溶液的多个部分。
-
公开(公告)号：EP2656848A1
公开(公告)日：2013-10-30
申请号：EP13165862.7
申请日：2013-04-29
IPC分类号： A61K31/70
CPC分类号： A61K31/7068 , A61K9/0019 , A61K47/02
摘要： A large volume infusion dosage form of gemcitabine, comprising a stable large volume solution of gemcitabine or its pharmaceutically acceptable salt in an aqueous vehicle filled in a large volume infusion container, wherein the solution is ready-to-be-infused.
-
25.发明公开
公开(公告)号：EP2566843A2
公开(公告)日：2013-03-13
申请号：EP11774543.0
申请日：2011-04-28
发明人： JADAV, Kanaksinh Jesingbhai , BHATT, RutvijManharlal , BORKHATARIA, Kamleshkumar Naranbhai , CHITTURI, Trinadha Rao , THENNATI, Rajamannar
IPC分类号： C07C231/02 , C07D487/04
CPC分类号： C07C229/34 , C07C227/14 , C07D487/04
摘要： The present invention provides a process for preparing a compound of formula (I), or a pharmaceutically acceptable salt thereof, having the
R -configuration, of formula (IA), or
S -configuration of formula (IB), selectively over the other enantiomer.摘要翻译： 本发明提供了制备式（I）的化合物或其药学上可接受的盐的方法，所述式（I）的化合物或其药学上可接受的盐具有式（IA）或式（IB）的S-构型的R构型， 。
-
公开(公告)号：EP1909770A2
公开(公告)日：2008-04-16
申请号：EP06780511.9
申请日：2006-02-22
IPC分类号： A61K9/52 , A61K31/4015
CPC分类号： A61K9/209 , A61K31/4015
摘要： The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising: a highly soluble high dose active ingredient consisting essentially of therapeutically effective amount of levetiracetam and a rate controlling means comprising a rate-controlling agent and optionally coating selected form (i) a active ingredient permeable coating surrounding the unit dosage form, and (ii) an active ingredient impermeable coating covering one or more surfaces but not all the surfaces of the unit dosage form, wherein the composition is in the form of a compact tablet and the levetiracetam or pharmaceutically acceptable derivative thereof is present in an amount ranging from about 55% to about 90% by weight of the tablet.
-
公开(公告)号：EP4387591A1
公开(公告)日：2024-06-26
申请号：EP22768958.5
申请日：2022-08-22
CPC分类号： A61K9/0048 , A61K9/1075 , A61K47/44 , A61K38/13 , A61P27/02
-
公开(公告)号：EP3578266B1
公开(公告)日：2024-06-19
申请号：EP19173089.4
申请日：2014-03-17
IPC分类号： A61P5/28 , A61P5/44 , A61P43/00 , A61K9/14 , A61K9/20 , A61K31/58 , C07J43/00 , A61K9/16 , A61P13/08 , A61P35/00 , A61K31/573
CPC分类号： A61K9/145 , A61K9/2018 , A61K9/1694 , A61K9/2013 , C07J43/003 , A61K31/58 , A61K31/573 , A61P13/08 , A61P35/00 , A61P43/00 , A61P5/28 , A61P5/44
-
公开(公告)号：EP4368175A2
公开(公告)日：2024-05-15
申请号：EP24153550.9
申请日：2015-09-03
发明人： SAMARTH, Kumar , PRASHANT, Kane , BALARAM, Bhowmich Subhas , KIRTI, Ganorkar , NISHIT, Patel , ANILRAO, Dubewar Ashish , MUKESHBHAI, Patel Umeshkumar
IPC分类号： A61K31/00
CPC分类号： A61M5/14 , A61M5/1408 , A61J1/16 , A61K9/0019 , A61K47/26 , A61K31/4745 , G16Z99/00 , A61J1/10 , A61P35/00 , G16H20/17
摘要： The present invention relates to a method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration.
The present invention further relates to a perfusion system comprising different sets of perfusion containers, each container comprising a ready-to-infuse, stable, sterile, aqueous perfusion solution of a drug, wherein the set of perfusion containers alone or in combination provides for direct intravenous administration of a desired dose of the drug to a patient in need thereof, such that the delivered dose is equal to or within ± 5% of the calculated dose.-
公开(公告)号：EP3474847B1
公开(公告)日：2022-09-07
申请号：EP17814874.8
申请日：2017-06-23
IPC分类号： A61K31/4164 , C07D233/64
-
-
-
-
-
-
-
-
-
搜索结果
74 条记录 (耗时 0.017 秒)
